Compare BioNano Genomics Inc (BNGO) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs DENTSPLY SIRONA Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while DENTSPLY SIRONA Inc trades at $11.46 (market cap $2.31B). The key difference: DENTSPLY SIRONA Inc is far larger — about 169.1× BioNano Genomics Inc's market cap, and DENTSPLY SIRONA Inc pays a 5.04% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | XRAY | |
|---|---|---|
Market Cap | $13.66M | $2.31B |
Sector | Health | Health |
52-Week High | $4.92 | $14.68 |
52-Week Low | $1.06 | $9.64 |
Enterprise Value | $16.26M | $4.39B |
Dividend Yield | — | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
DENTSPLY SIRONA (XRAY) trades at $11.32, down 2.92% today, with a bearish technical signal and mixed fundamentals. The company reported Q2 2026 EPS of $0.52, beating expectations, but revenue declined 4.1% year-over-year. Net income remains negative, though margins show improvement. The stock is near its consensus price target of $11.50, with support at $11 and resistance at $12.
Outlook is cautious; while cost controls and new partnerships offer potential, persistent revenue declines and high debt levels pose significant risks. Analyst sentiment is predominantly Hold, reflecting uncertainty around the turnaround plan's success amid weak dental market demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
